Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia

The use of tyrosine kinase inhibitors (TKI), including nilotinib, has revolutionized the treatment of chronic myeloid leukemia (CML). However current unmet clinical needs include combating activation of additional survival signaling pathways in persistent leukemia stem cells after long-term TKI ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Laidlaw, Kamilla M.E., Berhan, Samuel, Liu, Suhu, Silvestri, Giovannino, Holyoake, Tessa L., Frank, David A., Aggarwal, Bharat, Bonner, Michael Y., Perrotti, Danilo, Jørgensen, Heather G., Arbiser, Jack L.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5239504/
https://ncbi.nlm.nih.gov/pubmed/27438151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10541
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados